MCID: ISC004
MIFTS: 61

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 54 44 15 17 70
Acute Coronary Syndrome 70

Classifications:



External Ids:

Disease Ontology 12 DOID:326
MeSH 44 D007511
NCIt 50 C34738
SNOMED-CT 67 52674009
UMLS 70 C0022116 C0948089

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to limb ischemia and retinal ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000284946 (), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Development Angiotensin activation of ERK. The drugs Promethazine and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and endothelial, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 73 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1599)
# Related Disease Score Top Affiliating Genes
1 limb ischemia 33.3 VEGFA NOS3 HIF1A CXCL12 ACE
2 retinal ischemia 33.1 VEGFA SOD1 HIF1A CXCL12 CASP3
3 transient cerebral ischemia 33.1 SOD2 CDK5 CASP3
4 vascular disease 32.7 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
5 lipoprotein quantitative trait locus 32.6 VEGFA PON1 NOS3 HIF1A CASP3 ADORA1
6 nonarteritic anterior ischemic optic neuropathy 32.3 VEGFA NOS3 ACE
7 ischemic colitis 32.3 VEGFA HMOX1 HIF1A ACE
8 myocardial stunning 32.2 SOD1 ADORA3 ADORA1 ACE
9 microvascular complications of diabetes 5 32.2 VEGFA SOD2 PON1 NOS3 HIF1A CXCL12
10 myocardial infarction 32.2 VEGFA PON1 NOS3 HMOX1 HIF1A EPO
11 brain edema 32.1 VEGFA SOD1 HMOX1
12 microvascular complications of diabetes 2 32.1 EPO ACE
13 exudative vitreoretinopathy 1 32.1 VEGFA NOS3 HIF1A EPO
14 microvascular complications of diabetes 1 32.1 VEGFA HIF1A EPO CXCL12
15 coronary stenosis 32.0 PON1 CXCL12 ACE
16 peripheral artery disease 31.9 VEGFA NOS3 HMOX1 HIF1A ACE
17 hyperglycemia 31.9 SOD2 SOD1 PRKAA2 NOS3 HIF1A
18 respiratory failure 31.9 VEGFA SOD1 EPO ACE
19 testicular torsion 31.8 NOS3 CASP3 ACE
20 anoxia 31.8 SOD1 ADORA1
21 pulmonary edema 31.7 NOS3 HMOX1 HIF1A EPO ACE
22 end stage renal disease 31.6 VEGFA SOD2 PON1 NOS3 EPO ACE
23 arteriosclerosis 31.6 PON1 NOS3 HMOX1 HIF1A CXCL12 ACE
24 atherosclerosis susceptibility 31.6 VEGFA PON1 NOS3 ACE
25 carotid stenosis 31.6 VEGFA NOS3 ACE
26 pre-eclampsia 31.5 VEGFA SOD1 PON1 NOS3 HMOX1 HIF1A
27 kidney disease 31.5 VEGFA PON1 NOS3 HMOX1 EPO ACE
28 congestive heart failure 31.5 VEGFA NOS3 EPO ADORA1 ACE
29 chronic kidney disease 31.5 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
30 retinal vascular disease 31.4 VEGFA NOS3 HIF1A CASP3 ACE
31 vascular dementia 31.4 VEGFA SOD1 PON1 CASP3 APP ACE
32 stroke, ischemic 31.4 SOD2 PON1 NOS3 CXCL12 CASP3 ADORA3
33 pheochromocytoma 31.3 VEGFA HIF1A EPO EGR1 CASP3 ACE
34 heart disease 31.3 VEGFA SOD2 SOD1 PON1 NOS3 HMOX1
35 retinal artery occlusion 31.3 VEGFA HMOX1 ACE
36 macular retinal edema 31.3 VEGFA CXCL12 ACE
37 diabetes mellitus 31.3 VEGFA SOD2 SOD1 PON1 NOS3 MAPK8IP1
38 retinal vein occlusion 31.2 VEGFA CXCL12 ACE
39 pulmonary hypertension 31.2 VEGFA NOS3 HMOX1 HIF1A ACE
40 sleep apnea 31.2 VEGFA NOS3 HIF1A EPO ACE
41 type 2 diabetes mellitus 31.2 VEGFA SOD2 SOD1 PRKAA2 PON1 NOS3
42 neuroblastoma 31.2 VEGFA SOD1 HMOX1 HIF1A EGR1 CXCL12
43 eclampsia 31.2 VEGFA NOS3 ACE
44 diabetic neuropathy 31.1 VEGFA SOD2 PON1 EPO ACE
45 asphyxia neonatorum 31.1 HIF1A EPO CASP3
46 renovascular hypertension 31.1 SOD1 NOS3 HMOX1 ACE
47 hydrocephalus 31.1 VEGFA CASP3 APP ACE
48 deficiency anemia 31.1 SOD1 PON1 HMOX1 HIF1A EPO ACE
49 polycythemia 31.0 VEGFA HIF1A EPO ACE
50 diabetic macular edema 31.0 VEGFA SOD2 NOS3 HIF1A EPO

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness; polydipsia; angina pectoris; anoxemia

MGI Mouse Phenotypes related to Ischemia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADORA1 ADORA3 APP CASP3 CXCL12
2 behavior/neurological MP:0005386 10.45 ACE ADORA1 ADORA3 APP CASP3 CDK5
3 homeostasis/metabolism MP:0005376 10.44 ACE ADORA1 ADORA3 APP CASP3 CDK5
4 cellular MP:0005384 10.4 APP CASP3 CXCL12 EGR1 EPO HIF1A
5 hematopoietic system MP:0005397 10.37 ACE ADORA3 APP CASP3 CXCL12 EGR1
6 growth/size/body region MP:0005378 10.35 ACE ADORA1 APP CASP3 EGR1 HIF1A
7 immune system MP:0005387 10.34 ACE ADORA3 APP CASP3 CXCL12 EGR1
8 mortality/aging MP:0010768 10.28 ACE ADORA1 APP CASP3 CDK5 CXCL12
9 endocrine/exocrine gland MP:0005379 10.25 ACE CASP3 EGR1 HIF1A HMOX1 MAPK8IP1
10 integument MP:0010771 10.22 ADORA1 ADORA3 APP CASP3 CDK5 EGR1
11 liver/biliary system MP:0005370 10.17 ACE CXCL12 EGR1 EPO HIF1A HMOX1
12 nervous system MP:0003631 10.17 ACE ADORA1 APP CASP3 CDK5 CXCL12
13 muscle MP:0005369 10.11 APP CASP3 CXCL12 EPO HIF1A HMOX1
14 limbs/digits/tail MP:0005371 10 APP EGR1 EPO HIF1A HMOX1 NOS3
15 renal/urinary system MP:0005367 9.96 ACE ADORA1 ADORA3 CASP3 HIF1A HMOX1
16 reproductive system MP:0005389 9.9 ACE APP CASP3 CXCL12 EGR1 HMOX1
17 respiratory system MP:0005388 9.65 ADORA1 ADORA3 CASP3 CDK5 EGR1 EPO
18 vision/eye MP:0005391 9.28 ACE ADORA3 CASP3 EGR1 HIF1A NOS3

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 821)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 4 60-87-7 4927
2
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
3
Zolpidem Approved Phase 4 82626-48-0 5732
4
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
5
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
6
Capsaicin Approved Phase 4 404-86-4 1548943
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Nadroparin Approved, Investigational Phase 4
10
Etomidate Approved Phase 4 33125-97-2 36339 667484
11
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
12
Insulin glargine Approved Phase 4 160337-95-1
13
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
14
Tocopherol Approved, Investigational Phase 4 1406-66-2
15
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
16
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
17
Famotidine Approved Phase 4 76824-35-6 3325
18
Enoxaparin Approved Phase 4 9005-49-6 772
19
Fondaparinux Approved, Investigational Phase 4 104993-28-4
20
Thrombin Approved, Investigational Phase 4
21
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
22
Acetaminophen Approved Phase 4 103-90-2 1983
23
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
24
Nicotine Approved Phase 4 54-11-5 942 89594
25
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
26
Streptokinase Approved, Investigational Phase 4 9002-01-1
27
Pravastatin Approved Phase 4 81093-37-0 54687
28
Fenofibrate Approved Phase 4 49562-28-9 3339
29
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
30
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
31
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
32
Glyburide Approved Phase 4 10238-21-8 3488
33
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
34
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
35
Abciximab Approved Phase 4 143653-53-6
36
Polyestradiol phosphate Approved Phase 4 28014-46-2
37
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
38
Citalopram Approved Phase 4 59729-33-8 2771
39
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
40
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
41
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
42
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
43
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
44
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
45
Ramipril Approved Phase 4 87333-19-5 5362129
46
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
47
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
48
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
49
Hydroxychloroquine Approved Phase 4 118-42-3 3652
50
Sodium citrate Approved, Investigational Phase 4 68-04-2

Interventional clinical trials:

(show top 50) (show all 5592)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
3 A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome Unknown status NCT03007524 Phase 4 High dose Rosuvastatin;Low dose Rosuvastatin
4 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
5 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
6 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
7 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
8 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
9 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
10 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
11 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
12 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
13 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
14 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
15 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
16 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
17 Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. Unknown status NCT02341729 Phase 4 ticagrelor
18 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker
19 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
20 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
21 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
22 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
23 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI(EARLY-MYO II) Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
24 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
25 Comparative Effectiveness and Safety Analysis of Low-dose and Standard-dose Ticagrelor in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT03381755 Phase 4 half-dose ticagrelor;standard-dose ticagrelor
26 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
27 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
28 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
29 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
30 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
31 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
32 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
33 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
34 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
35 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
36 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
37 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
38 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
39 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
40 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
41 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
42 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
43 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
44 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
45 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
46 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
47 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
48 Randomized Controlled Study of a Rapid "Rule Out" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes Unknown status NCT00933400 Phase 4
49 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4
50 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

40
Heart, Brain, Endothelial, Liver, Kidney, Bone Marrow, Bone

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 54400)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 54 61
20235222 2010
2
Vascular responses to hypoxia and ischemia. 54 61
19729615 2010
3
Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. 61 54
20107113 2010
4
Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia. 54 61
20206813 2010
5
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. 54 61
20298924 2010
6
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 61 54
19836457 2010
7
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 54 61
20133634 2010
8
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 54 61
20190407 2010
9
Allopurinol, xanthine oxidase, and cardiac ischemia. 54 61
19794315 2009
10
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 54 61
19920350 2009
11
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 61 54
19917352 2009
12
Up-regulation of ICAM-1 during cold ischemia triggers early neutrophil infiltration in human pancreas allograft reperfusion. 54 61
19917355 2009
13
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 61 54
19622751 2009
14
Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. 61 54
19628785 2009
15
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 54 61
19576596 2009
16
Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. 54 61
19862336 2009
17
Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. 54 61
19528256 2009
18
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 61 54
19682205 2009
19
Increased expression of monocarboxylate transporter 1 after acute ischemia of isolated, perfused mouse hearts. 54 61
19604494 2009
20
Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. 61 54
19498441 2009
21
Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. 54 61
19628067 2009
22
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 61 54
19596001 2009
23
Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. 54 61
19539448 2009
24
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 61 54
19443639 2009
25
Use of changes in B-type natriuretic peptides to detect ischemia in selected patients. 61 54
18632168 2009
26
Repeated, but not single, VEGF gene transfer affords protection against ischemic muscle lesions in rabbits with hindlimb ischemia. 61 54
19340019 2009
27
Dietary sources of nitrite as a modulator of ischemia/reperfusion injury. 61 54
19212422 2009
28
The neuronal apoptotic death in global cerebral ischemia in gerbil: important role for sodium channel modulator. 61 54
19115407 2009
29
Effects of overexpression of antioxidants on the release of cytochrome c and apoptosis-inducing factor in the model of ischemia. 61 54
19429031 2009
30
Angiopoietin-1 in the treatment of ischemia and sepsis. 54 61
18791498 2009
31
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 61 54
19371824 2009
32
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 61 54
19279473 2009
33
Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. 61 54
19183269 2009
34
Expression of tissue-type transglutaminase (tTG) and the effect of tTG inhibitor on the hippocampal CA1 region after transient ischemia in gerbils. 61 54
19368835 2009
35
Neutrophil elastase inhibitor attenuates hippocampal neuronal damage after transient forebrain ischemia in rats. 54 61
19168036 2009
36
Region-specific sensitivity of the spinal cord to ischemia/reperfusion: the dynamic of changes in catalytic NOS activity. 54 61
19340549 2009
37
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. 54 61
19094989 2009
38
NV1FGF, a pCOR plasmid-based angiogenic gene therapy for the treatment of intermittent claudication and critical limb ischemia. 61 54
19333884 2009
39
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 61 54
19028502 2009
40
Plasma brain natriuretic peptide at rest and after adenosine-induced myocardial ischemia in normotensive and essential hypertensive patients with suspected coronary artery disease. 61 54
18951935 2009
41
Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. 61 54
19116149 2009
42
[Biochemical markers in the diagnosis of acute coronary syndrome]. 54 61
19681456 2009
43
Agent-based model of therapeutic adipose-derived stromal cell trafficking during ischemia predicts ability to roll on P-selectin. 61 54
19247427 2009
44
Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. 61 54
19117950 2009
45
Ischemia alters the expression of connexins in the aged human brain. 61 54
19794823 2009
46
Early iNOS impairment and late eNOS enhancement during reperfusion following 2.49 MHz continuous ultrasound exposure after ischemia. 61 54
18595762 2009
47
Human adrenomedullin combined with human adrenomedullin binding protein-1 is protective in gut ischemia and reperfusion injury in the rat. 54 61
18948146 2009
48
TEMPOL, a membrane-permeable radical scavenger, attenuates gastric mucosal damage induced by ischemia/reperfusion: a key role for superoxide anion. 61 54
19087872 2009
49
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 54 61
18812468 2009
50
Upregulation of stromal cell-derived factor 1 (SDF-1) expression in microvasculature endothelial cells in retinal ischemia-reperfusion injury. 54 61
18709383 2008